Christine Chevreau

Institut universitaire du cancer de Toulouse Oncopole — France

Medicine · Health Sciences

24h-index3.3kcitations204works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(92), Cancer Immunotherapy and Biomarkers(48), Bladder and Urothelial Cancer Treatments(24), Renal and related cancers(23), Sarcoma Diagnosis and Treatment(19)

Publications204 total

Figure S1 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Supplementary Tables TS1-23 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S4 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S8 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S6 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S3 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S5 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S2 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Figure S7 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025Open Access
Table S2 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Supplementary Figure Annotations from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S3 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Supplementary Figures from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Table S4 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025Open Access
Postoperative radiotherapy in patients with R0 resection of soft tissue sarcoma: results from the European sarcoma CONTICABASE analysis
British Journal of Radiology·2025Open Access
CO9.2 - Bayesian model using bivariate efficacy-tolerability outcome in patients with angiosarcoma to determine the safe most successful dose of propranolol in combination with metronomic fixed-dose cyclophosphamide: PROPAN a Phase I-II sequential trial
Journal of Epidemiology and Population Health·2025
Primary ovarian leiomyosarcoma: results from an analysis by the French Sarcoma Group (Ovarian SArcoma MAnagement – OSAMA Study)
International Journal of Gynecological Cancer·2025· 1 citedOpen Access
Metastatic Pure Seminomas With Early Relapse: Prognostic Roles of High Dose Chemotherapy and Surgery of Residual Disease
Clinical Genitourinary Cancer·2025
Supplementary Figures from Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear-cell renal cell carcinoma
2024Open Access
page 1 of 11Next →

Frequent Co-authors

Brigitte Laguerre(16), Gwénaëlle Gravis(14), Stéphane Oudard(13), Philippe Barthélémy(12), Laurence Albigès(10), Nicolas Penel(9), Florence Joly(9), Hakim Mahammedi(9), Frédéric Rolland(9), Aude Fléchon(9), Emmanuelle Bompas(8), Delphine Borchiellini(8), Marine Gross‐Goupil(8), Maud Toulmonde(7), Jean‐Yves Blay(7), Antoîne Italiano(7), Catherine Sautès‐Fridman(7), Wolf H. Fridman(7), Sylvie Négrier(7), Yann Vano(7)